Autoimmune diabetes vaccine (Diamyd) - Diamyd Medical

Drug Profile

Autoimmune diabetes vaccine (Diamyd) - Diamyd Medical

Alternative Names: Antigen-based therapy (ABT) - Diamyd Medical; Diabetes-mellitus-vaccine-Diamyd-Medical; Diabetes-mellitus-vaccine-Diamyd-Therapeutics; Diamyd; GAD-65 - Diamyd Medical; GAD-Alum vaccine; GAD-Alum vaccine - Diamyd Medical; GAD-antigen therapy (Diamyd); rhGAD65 - Diamyd Medical

Latest Information Update: 19 Apr 2017

Price : $50

At a glance

  • Originator Diamyd Medical
  • Developer Diamyd Medical AB; Linkoping University; Lund University; University of Alabama at Birmingham
  • Class Antihyperglycaemics; Diabetes mellitus vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Type 1 diabetes mellitus
  • Phase II Latent autoimmune diabetes in adults

Most Recent Events

  • 05 Apr 2017 Updated efficacy data from the phase II DIABGAD-I trial in Type-I diabetes mellitus released by Diamyd Medical
  • 05 Apr 2017 Updated efficacy data from the phase III European trial in Type I diabetes mellitus released by Diamyd Medical
  • 29 Mar 2017 Efficacy data from a phase I trial in Type-1 diabetes mellitus released by Diamyd
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top